Talaris Therapeutics, formerly Regenerex, is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/18/19 | $100,000,000 | Series A |
Blackstone Life Sciences Longitude Capital Qiming Venture Partners | undisclosed |
| 10/06/20 | $115,000,000 | Series B |
Aisling Capital BlackRock Blackstone Life Sciences Cormorant Asset Management Eventide Asset Management Invus Logos Capital Longitude Capital Pamoja Capital Qiming Venture Partners Surveyor Capital Viking Global Investors | undisclosed |
